BioSpace News Archive

Praxis Precision Medicines, Inc. announced the closing of the underwritten public offering of shares of common stock and pre-funded warrants, including the full exercise of the underwriters’ overallotment option.

Biotech start-up, Psylo, announced today that it has entered into a Sponsored Research Agreement with global Japanese pharmaceutical company, Daiichi Sankyo (DSNKY), to support the advancement of psychiatric medicines for patients struggling with chronic mental illness.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced pelareorep has been selected for inclusion as a new investigational treatment in Precision PromiseSM, an innovative adaptive Phase 3 clinical trial.

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity.

Ferring Pharmaceuticals announced that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovative medicines by the US Food and Drug Administration.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that the first patient has been enrolled in a 4-arm Phase 2 trial2 of AlenuraTM, comparing the product candidate to both of its individual components 3 as well as placebo.

Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced that the first patient has been enrolled in a pivotal, multicenter U.S. Phase II/III trial of AntiBKV, MTx’s antibody therapeutic that targets BK polyomavirus infection in renal transplant patients.

Poolbeg Pharma announces an update to its Oral Vaccine Programme following the award of non-dilutive grant funding by the Irish Government’s Disruptive Technologies Innovation Fund in November 2022, as part of the Poolbeg led EncOVac Consortium.

Reviva Pharmaceuticals Holdings, Inc. announced over 80% of patients have been enrolled in the pivotal Phase 3 RECOVER study evaluating brilaroxazine for the treatment of schizophrenia.

SOPHiA GENETICS announced that Ankara Etlik City Hospital, the largest hospital in the capital city of Turkey, is live on the SOPHiA DDM™ Platform.